ASCO GU 2021 News : Episode 2

ASCO GU 2021 News: Drs. Bradley McGregor, David Braun, and

Video

Related Videos
Joaquim Bellmunt, MD, PhD
Joaquim Bellmunt, MD, PhD
Kenneth C. Anderson, MD
Haeseong Park, MD, MPH
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Jennifer Brown, MD, PhD
Rebecca L. Porter, MD, PhD
Wenxin (Vincent) Xu, MD,
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Related Content
Kenneth C. Anderson, MD

The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma

May 13th 2024
Article
Andrew J. Wagner, MD, PhD, medical director, Ambulatory Oncology, senior physician, Dana-Faber Cancer Institute; associate professor, medicine, Harvard Medical School

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

March 28th 2024
Podcast
Ursula Matulonis, MD

New $15 Million Grant to Dana-Farber Scientists Supports Research into Innovative Approaches to Endometrial Cancer Treatment

May 10th 2024
Article
Matthew S. Davids, MD, MMSc

FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL

January 25th 2024
Podcast
Matthew S. Davids, MD, MMSc

Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL

May 6th 2024
Article
Leland Metheny, MD, Case Western Reserve University

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma

May 2nd 2024
Article